AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1590284
Drug: Sustained-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release morphine sulfate (SRMS) tablets, 30 mg every 12 hours
Trial: 1590284
Drug: Immediate-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release morphine sulfate (IRMS) solution, same mg/24 hours dose, every 4 hours
Trial: 1590284
Drug: Sustained-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release morphine sulfate (SRMS) tablets
Trial: 1590284
Drug: Immediate-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release morphine sulfate (IRMS) solution
Trial: 12721256
Drug: Delayed Intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed Intensification (DI) phase of therapy for 7 weeks
Trial: 12721256
Drug: Delayed Intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed Intensification (DI) phase of therapy
Trial: 10474123
Drug: Pulsatile GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile GnRH infusion (100 ng/kg i.v. every 90 min for 2 weeks)
Trial: 8709374
Drug: Transurethral resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral resection plus mitomycin C (20 mg/50 ml sodium chloride, every 2 weeks during year 1 and once a month during year 2)
Trial: 8709374
Drug: Transurethral resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral resection plus bacillus Calmette-Guerin (BCG) (120 mg/50 ml sodium chloride, instilled once a week for 6 weeks and once a month for 4 months)
Trial: 8709374
Drug: All therapy
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All therapy groups (mitomycin C, BCG, and transurethral resection only)
Trial: 1855607
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of intrapartum ampicillin intravenously
Trial: 30794953
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist protocol with HMG and low dose (100IU/day) hCG
Trial: 30794953
Drug: Short GnRH-agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short GnRH-agonist protocol with HMG and low dose (100IU/day) hCG
Trial: 28462571
Drug: Combined endurance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined endurance running and strength training program twice a week (ES60)
Trial: 27082736
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections of anti-VEGF drugs (ranibizumab and/or aflibercept)
Trial: 27082736
Drug: Cumulative number
RxNorm normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cumulative number of aflibercept injections
Trial: 27082736
Drug: Cumulative number
RxNorm normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cumulative number of intravitreal injections of overall anti-VEGF drugs
Trial: 19786130
Drug: SB-423557 (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-423557 (daily oral administration)
Trial: 19786130
Drug: SB-423562 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-423562 (single intravenous dose)
Trial: 19786130
Drug: SB-423557 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-423557 (single oral dose)
Trial: 19786130
Drug: SB-423557 (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-423557 (higher doses)
Trial: 17479288
Drug: Topotecan (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (1.0 mg/m(2)/day 168‐h continuous infusion), cyclophosphamide (100 mg/m(2)/day 1‐h infusion days 1‐7), etoposide (100 mg/m(2)/day 1‐h infusion days 8‐10)
Trial: 15209391
Drug: Vaginal washing
RxNorm normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal washing with povidone iodine and insertion of chloramphenicol vaginal tablets in women with IL-8 elevations (Group B)
Trial: 15209391
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (Group A, no treatment)
Trial: 15209391
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (Group C, treatment not specified)
Trial: 9830832
Drug: L-glutamine (GLN)
DrugBank: L-Glutamine (DB00130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-glutamine (GLN) 0.03 g.kg body mass‐1
Trial: 9830832
Drug: L-glutamine (GLN)
DrugBank: L-Glutamine (DB00130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-glutamine (GLN)
Trial: 2724486
Drug: Psyllium hydrophilic
RxNorm normalized name: PSYLLIUM HYDROPHILIC MUCILLOID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium hydrophilic mucilloid (3.4 g three times per day for 8 weeks)
Trial: 25311913
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of DF and SMM
Trial: 16965776
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg and placebo
Trial: 16965776
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg and ramipril 10 mg
Trial: 16965776
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (simvastatin 20 mg and ramipril 10 mg)
Trial: 7486293
Drug: Extrapleural analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrapleural analgesia with 20 mL of 0.5% bupivacaine
Trial: 7486293
Drug: Intrpleural analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrpleural analgesia with 20 mL of 0.5% bupivacaine
Trial: 3148149
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (800 mg)
Trial: 6958473
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline pretreatment
Trial: 15785303
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 4 IU every other day for 3 months
Trial: 11989050
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac 60 mg i.v. 30 min before ESWL
Trial: 11989050
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl 100 micrograms i.v. 3 min before ESWL
Trial: 9803444
Drug: Antenatal TRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal TRH treatment
Trial: 2551765
Drug: Ursodeoxycholic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid, 10 mg/kg.day
Trial: 31349003
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg daily once or twice based on BMI) as an add-on to standard therapy
Trial: 31349003
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (SAMA + SABA inhaled and ICS + LABA or ICS + LABA + LAMA)
Trial: 25514794
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg daily)
Trial: 21109771
Drug: Azacitidine (AZA)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine (AZA) and Valproic Acid (VPA) combination therapy
Trial: 21173560
Drug: Clevudine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clevudine (30 mg once daily for more than 48 weeks)
Trial: 21173560
Drug: Entecavir (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir (0.5 mg once daily for more than 48 weeks)
Trial: 21173560
Drug: Lamivudine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (100 mg once daily for more than 48 weeks)
Trial: 12009718
Drug: Urate concentration
RxNorm normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Urate concentration greater than 0.31 mmol.l(-1)
Trial: 12009718
Drug: Urate concentration
RxNorm normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Urate concentration greater than 0.38 mmol.l(-1)
Trial: 12009718
Drug: Raised urate
RxNorm normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Raised urate in patients not on diuretics
Trial: 7843758
Drug: Amlodipine and
RxNorm normalized name: amlodipine and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine and Lisinopril
Trial: 2588996
Drug: 1:200,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:200,000 epinephrine with 10 ml of 1.5% lidocaine
Trial: 22093196
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg QD (2.5 mg in subjects with moderate/severe renal impairment)
Trial: 15563390
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (extended lateral approach with subchondral fixation, plating, and bone grafting when necessary)
Trial: 15563390
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (ice, elevation, and rest without closed reduction)
Trial: 9153347
Drug: Fasting administration
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting administration of 400 mg racemic ibuprofen
Trial: 9153347
Drug: Postprandial administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postprandial administration of 400 mg racemic ibuprofen
Trial: 3608379
Drug: Chlorpropamide 250
RxNorm normalized name: chlorpropamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpropamide 250 mg twice daily for 2 days
Trial: 29460783
Drug: Glucose 25
RxNorm normalized name: glucose 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 25 g
Trial: 25658956
Drug: Tasimelteon 20
RxNorm normalized name: tasimelteon 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasimelteon 20 mg capsule
Trial: 25658956
Drug: Tasimelteon 2
RxNorm normalized name: tasimelteon 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasimelteon 2 mg IV infusion over 30 minutes
Trial: 25658956
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (oral and IV)
Trial: 20377407
Drug: Reduced-dose (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose (9 microg, 0.3 mL) ID injection
Trial: 20377407
Drug: Reduced-dose (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose (9 microg, 0.3 mL) IM injection
Trial: 20377407
Drug: Standard-dose (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose (15 microg each of 3 hemagglutinin vaccine antigens in 0.5 mL) IM injection
Trial: 20377407
Drug: Two reduced-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two reduced-dose (4.5 microg, 0.15 mL) ID injections
Trial: 18540358
Drug: Apheresis therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apheresis therapy (Plasmapheresis and Cytapheresis)
Trial: 16796986
Drug: 21/7 oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21/7 oral contraceptive regimen
Trial: 15084614
Drug: ATRA and
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA and chemotherapy (CT)
Trial: 8319667
Drug: Iron-enriched milk
RxNorm normalized name: iron succinyl milk protein complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-enriched milk (12 mg/l)
Trial: 8319667
Drug: Control milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control milk (1 mg/l)
Trial: 30995895
Drug: Half saline-bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half saline-bicarbonate infusion
Trial: 30146142
Drug: ePST (computer-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ePST (computer-guided Problem-Solving Treatment)
Trial: 27236864
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of intravenous acetaminophen every 6 hours for 24 hours
Trial: 22158433
Drug: Valsartan (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (160 mg/d)
Trial: 15841830
Drug: Dialectical behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behavior therapy for depressed older adults
Trial: 8830068
Drug: Clonidine plus
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine plus haloperidol (20 mg/day)
Trial: 2919772
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine + 2 mg butorphanol
Trial: 2919772
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine + 0 mg butorphanol
Trial: 2919772
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine + 3 mg butorphanol
Trial: 31996813
Drug: 0.3% NaCl
RxNorm normalized name: LVP solution Dextrose 5% with 0.3% NaCl intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% NaCl solution with 0.3% MSG
Trial: 31996813
Drug: 0.6% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6% NaCl solution with 0.3% MSG
Trial: 31996813
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution with 0.3% MSG
Trial: 31996813
Drug: 0.3% NaCl
RxNorm normalized name: LVP solution Dextrose 5% with 0.3% NaCl intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% NaCl solution without MSG
Trial: 31996813
Drug: 0.6% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6% NaCl solution without MSG
Trial: 31996813
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution without MSG
Trial: 28708734
Drug: 0.1‐mmol/kg bw
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1‐mmol/kg bw of gadoterate (full dose)
Trial: 28708734
Drug: 0.05‐mmol/kg bw
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05‐mmol/kg bw of gadobenate (half dose)
Trial: 25089928
Drug: Cangrelor infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cangrelor infusion (bolus plus 2-h infusion)
Trial: 25089928
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg dose at 1h, 1.5h, 2h, or 2.5h after cangrelor)
Trial: 25089928
Drug: Prasugrel (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (10 mg daily for 5 or 6 days)
Trial: 25089928
Drug: Cangrelor infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cangrelor infusion (on study day 8)
Trial: 19341849
Drug: One cycle
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One cycle of pills at initiation, followed by counseling and a three-pack resupply
Trial: 11695951
Drug: Melatonin 10
RxNorm normalized name: melatonin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 10 mg/d for 6 weeks
Trial: 9663244
Drug: Autotransplantation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autotransplantation of 60 mg of a diffuse hyperplastic parathyroid gland into subcutaneous forearm tissue (Group A)
Trial: 9663244
Drug: Autotransplantation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autotransplantation of 15 pieces (60 mg) of 1 mm3 tissue into forearm muscles (Group B)
Trial: 15613018
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg quercetin‐4'‐O‐beta‐D‐glucoside
Trial: 15613018
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg quercetin‐4'‐O‐beta‐D‐glucoside
Trial: 10637204
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of carbachol
Trial: 10637204
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of L-NMMA
Trial: 10637204
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of carbachol followed by coinfusion with L-NMMA
Trial: 9314339
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (ragweed immunotherapy)
Trial: 9314339
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (initial immunotherapy)
Trial: 28257614
Drug: Cortisone Injection
RxNorm normalized name: hydrocortisone Injection
DrugBank: Cortisone (DB14681)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisone Injection
Trial: 28257614
Drug: Medication intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication intake for pain
Trial: 25361981
Drug: Low-ER receptor
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-ER receptor signaling and apoptosis gene module scores
Trial: 24289059
Drug: New Medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Medicine Service (NMS) intervention comprising pharmacist-delivered support for a newly prescribed medicine
Trial: 21828126
Drug: High-dose daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose daunorubicin (HD-DN, 90 mg/m² per day times 3 days)
Trial: 21828126
Drug: Standard-dose daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose daunorubicin (SD-DN, 45 mg/m² per day times 3 days)
Trial: 21828126
Drug: High-dose daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose daunorubicin (HD-DN)
Trial: 21828126
Drug: Standard-dose daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose daunorubicin (SD-DN)
Trial: 9340641
Drug: Alcohol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1.5 ml per kg of body weight of 80 proof vodka)
Trial: 8343351
Drug: No complementary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No complementary treatment (Control)
Trial: 28976265
Drug: Gr.Suppl.5 -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gr.Suppl.5 - 5 µg daily dose of VitD3-fortified yogurt
Trial: 28976265
Drug: Gr.Suppl.10 -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gr.Suppl.10 - 10 µg daily dose of VitD3-fortified yogurt
Trial: 18395907
Drug: Prepacol (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepacol (sodium phosphate and bisacodyl) preparation in 26 patients
Trial: 18395907
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Prepacol preparation) in 26 patients
Trial: 15562015
Drug: Calcium (500
RxNorm normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (500 mg twice daily with meals)
Trial: 9798657
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (Group A, n = 11)
Trial: 869086
Drug: Smoking withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking withdrawal clinic protocols (various drugs and education methods)
Trial: 30959006
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.2 mg/kg (group MD)
Trial: 30959006
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin 0.4 mg/kg (group M)
Trial: 30959006
Drug: Oral multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral multivitamin tablet as placebo (group P)
Trial: 29336763
Drug: Daily chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily chlorhexidine gluconate (CHG) baths and mupirocin (MUP) ointment to the nares
Trial: 29336763
Drug: Soap and
RxNorm normalized name: Green soap and industrial methylated spirit only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soap and water baths and placebo ointment
Trial: 24517052
Drug: Xinfeng Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng Capsule (XC) 3 tablets thrice daily for 12 weeks